Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;31(1):13-29.
doi: 10.1016/j.hoc.2016.08.006.

Lung Cancer Biomarkers

Pamela Villalobos  1 , Ignacio I Wistuba  2
Affiliations
Review

Lung Cancer Biomarkers

Pamela Villalobos et al. Hematol Oncol Clin North Am. 2017 Feb.

Abstract

The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it is possible to identify subsets of patients who benefit from targeted molecular therapies. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has led to accelerated development of new drugs for lung cancer treatment. This article focuses on clinically relevant cancer biomarkers as targets for therapy and potential new targets for drug development.

Keywords: Biomarkers; Genotyping; Lung cancer; Molecular targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative examples of histology of lung adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) histology and biomarker analysis using IHC. ADC tumor tissue shows positive expression for TTF-1 (nuclear), PD-L1 (membrane and cytoplasm), and ALK (cytoplasm); p40 shows negative expression. SqCC shows positive expression for p40 (nuclear) and PD-L1 (membrane and cytoplasm); p40 and ALK expression are negative (20x magnification).
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. - PubMed
    1. American Cancer Society [May 25, 2016];Cancer Facts & Figures 2015. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2....
    1. Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med. 2013;137(9):1191–1198. - PubMed
    1. Fujimoto J, Wistuba II. Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol. 2014;31(4):306–313. - PMC - PubMed
    1. Kerr KM, Bubendorf L, Edelman MJ, et al. Panel Members. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–1690. - PubMed

Substances